MiR-144/451 attenuates lipopolysaccharide-induced lung inflammation by downregulating Rac1 and STAT-3 in macrophages

Sheng He1, Xiang Gao2, Lei Yang2,3

  • 1Guangxi Key Laboratory of Basic Research on Prevention and Control of Birth Defects and Guangxi Key Laboratory of Reproductive Health and Birth Defects Prevention, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.

Insights

MicroRNAs miR-144/451 act as anti-inflammatory factors in lung diseases. Their absence worsens lipopolysaccharide-induced lung inflammation by increasing oxidative stress and inflammatory markers.

Area of Science:

  • Immunology
  • Molecular Biology
  • Respiratory Medicine

Background:

  • MicroRNAs are crucial regulators in inflammatory diseases.
  • Lung inflammation, often triggered by agents like lipopolysaccharide (LPS), involves complex molecular pathways.

Purpose of the Study:

  • To investigate the role of microRNAs miR-144/451 in lipopolysaccharide (LPS)-induced lung inflammation.
  • To elucidate the molecular mechanisms by which miR-144/451 regulate inflammatory responses in the lungs.

Main Methods:

  • Utilized a mouse model of LPS-induced lung inflammation.
  • Performed gene knockout (KO) of miR-144/451 in mice and conducted loss-of-function experiments.
  • Analyzed inflammatory markers, oxidative stress indicators, and key signaling molecules (Rac1, STAT-3) in lung tissues and macrophages.
  • Employed cell culture (RAW264.7 cells) and luciferase reporter assays.

Main Results:

  • miR-144/451 knockout exacerbated LPS-induced lung inflammation and oxidative stress.
  • LPS decreased miR-451 expression, while miR-451 overexpression reduced inflammatory cytokine production and reactive oxygen species (ROS).
  • miR-144/451 negatively regulate Rac1 and directly target STAT-3, a key inflammatory signaling molecule.

Conclusions:

  • miR-144/451 function as critical anti-inflammatory factors in LPS-induced lung inflammation.
  • The anti-inflammatory effect is mediated through the downregulation of Rac1 and STAT-3 pathways.
  • These findings highlight miR-144/451 as potential therapeutic targets for lung inflammatory diseases.